

# Index

*Please note:* page numbers in **bold type** indicate tables.

- acquired aplastic anemia, 43–46
  - ancillary diagnostic testing, 45
  - classification and grading, **45**
  - clinical features, 45
  - differential diagnosis, **46**, 152
  - knowledge gaps, 46
  - microscopic features, 45
  - pathophysiology, 46
  - prognosis and treatment, 46
- acquired immunodeficiency syndrome (AIDS), 59
  - fungal infections, 85
  - lymphoma increased in, 61
  - see also under human immunodeficiency virus (HIV).*
- acquired pure red blood cell aplasia (PRCA), 28
  - causes, **29**
- acute leukemias of ambiguous lineage (ALALs), 199–203
  - acute undifferentiated leukemia (AUL), 199–201
  - classification, **199**
  - mixed-phenotype acute leukemia (MPAL), 201–203
  - not otherwise specified (ALALs, NOS), 203
  - see also under individual conditions.*
- acute lymphoblastic leukemia (ALL)
  - classification, 108
  - cytogenetic testing, 108
  - differential diagnosis, 142
- acute megakaryoblastic leukemia (AMKL), differential diagnosis, 184
- acute monocytic leukemia, differential diagnosis, 160
- acute myeloid leukemia (AML)
  - classification, **156**
  - classification of AML subtypes, 155, **156**
  - cytogenetic testing, 112–113
  - differential diagnosis, 56, 127
  - Down syndrome-associated myeloid proliferations, 183–186
  - with myelodysplasia-related changes (AML-MRC), 173–175
  - clinical features, 173
  - diagnostic criteria, **174**
  - differential diagnosis, 173
  - genetic features, 173
  - immunophenotype, 173
  - pathologic features, 173
  - prognosis, 175
- myeloid sarcoma (MS), 181–183
- not otherwise specified (AML, NOS), 177
- with recurrent genetic abnormalities, 155–173
  - acute promyelocytic leukemia (APL)
    - with *PML-RARA*, 160–162
    - clinical features, 158
    - genetic features, 159
    - immunophenotype, 158–159
    - pathologic features, 158
    - prognosis and treatment, 160
  - BCR-ABL1*, 168–169
    - clinical features, 168
    - genetic features, 169
    - immunophenotype, 169
    - pathological features, 168
    - prognosis and treatment, 169
  - biallelic mutation of *CEBPA*, 171–172
    - clinical features, 171
    - genetic features, 172
    - immunophenotype, 171
    - pathologic features, 171
    - prognosis, 172
  - mutated *NPM1*, 170–171
    - clinical features, 170
    - genetic features, 171
    - immunophenotype, 171
    - pathologic features, 170
    - prognosis, 171
  - mutated *RUNX1*, 172–173
    - clinical features, 172
    - genetic features, 172
    - immunophenotype, 172
    - pathologic features, 172
    - prognosis, 172
- AML (megakaryoblastic) with *t(1;22)(p13.3, 167)*
  - clinical features, 167
  - genetic features, 167
  - immunophenotype, 167
  - pathologic features, 167
  - prognosis and treatment, 167
- inv(16)(p13.1q22) or (16;16)(p13.1, 158–160)*
  - clinical features, 160
  - genetic features, 160–162
  - immunophenotype, 160
  - pathologic features, 160
  - prognosis and treatment, 162
- inv(3)(q21.3;q26.2) or t(3;3)(q21.3, 165–167)*
  - clinical features, 165
  - differential diagnosis, 167
  - genetic features, 166
  - immunophenotype, 166
  - pathologic features, 166
  - prognosis, 167
- risk of development
  - for aplastic anemia patients, 46
  - for DBA patients, 25
  - for FA patients, 39
  - for leukemoid reaction patients, 62
  - for SCN patients, 28, 31
  - for SDS patients, 42
- therapy-related myeloid neoplasms (t-MNs), 175–177
- acute myeloid leukemia (AML), with recurrent genetic abnormalities
  - t(8;16)(p11, 169–170)*
    - clinical features, 169
    - genetic features, 170
    - immunophenotype, 170
    - pathologic features, 169
    - prognosis, 170
  - t(8;21)(q22, 156–158)*
    - clinical features, 156
    - genetic features, 158
    - immunophenotype, 156
    - pathologic features, 156
    - prognosis and treatment, 158
  - t(9;11)(p21.3, 162–164)*
    - clinical features, 162
    - differential diagnosis, 163
    - genetic features, 163
    - immunophenotype, 163
    - pathologic features, 163

- prognosis, 164  
 t(6;9)(p23, 164–165  
   clinical features, 164  
   differential diagnosis, 165  
   genetic features, 165  
   immunophenotype, 165  
   pathologic features, 164  
   prognosis and treatment, 165  
 acute undifferentiated leukemia (AUL),  
   199–201  
   clinical features, 199  
   epidemiology, 199  
   genetic features, 201  
   immunophenotype, 200  
   pathologic features, 199  
   prognosis, 201  
 adhesion molecules, role in  
   hematopoiesis regulation, 3  
 Alder-Reilly anomaly, 56–57  
   ancillary diagnostic testing, 57  
   clinical features, 56  
   differential diagnosis, 56  
   microscopic features, 56  
   pathogenesis, 56  
   prognosis, 57  
 ALK-negative lymphoma, 266–269  
 ALK-positive histiocytosis, 338  
 ALK-positive lymphoma, 263–266  
 allergic vasculitis, lymphoid hyperplasia  
   and, 81  
 anaplastic large cell lymphoma (ALCL)  
   ALK-negative, 266–269  
   clinical features, 268  
   differential diagnosis, 269, 271  
   epidemiology, 268  
   genetic features, 268–269  
   immunophenotype, 268  
   morphologic features, 268  
   prognosis, 269  
   ALK-positive, 263–266  
   clinical features, 263  
   differential diagnosis, 264, 346  
   epidemiology, 263  
   genetic features, 264  
   immunophenotype, 264  
   morphologic features, 263–264  
     ALCL common/anaplastic  
     pattern, 263  
     composite pattern, 264  
     Hodgkin-like pattern, 264  
     lymphohistiocytic pattern, 263  
     small-cell pattern, 264  
   prognosis and treatment, 266  
   differential diagnosis, 243  
 ancillary tests, 97–118  
   cytogenetics, 107–114  
   flow cytometry, 97–107  
   immunohistochemistry  
     (IHC), 107  
   molecular genetics, 114–118  
     *see also under individual tests.*  
 anemia, 9  
   acquired anemia, 17–23  
   congenital dyserythropoietic anemia  
     (CDA), 12–14  
   congenital sideroblastic anemia (CSA),  
     15–16  
   constitutional anemia and  
     hemoglobinopathy, 9–17  
   glucose-6-phosphate dehydrogenase  
     (G6PD) deficiency, 16–17  
   hereditary elliptocytosis (HE), 15  
   hereditary spherocytosis (HS), 14–15  
   paroxysmal nocturnal hemoglobinuria  
     (PNH), 22–23  
   parvovirus B19 infection-produced red  
     cell aplasia, 21–22  
   sickle cell anemia, 11–12  
   thalassemias, 9–11  
   vitamin B12 and folate deficiency, 18–20  
   *see also under individual conditions.*  
 angiofollicular hyperplasia, *see* Castleman  
   disease (CD).  
 aorta-gonadal-mesonephrons (AGM)  
   region, 1  
 ataxia-telangiectasia (AT), 296  
 atypical chronic myeloid leukemia  
   (aCML), 123  
   differential diagnosis, 123  
 atypical marginal zone hyperplasia,  
   differential diagnosis, 253  
 autoimmune lymphoproliferative  
   syndrome (ALPS), 78–81, 296  
   clinical features, 78  
   differential diagnosis, 80  
   flow cytometry testing, 103  
   immunophenotype, 298  
   pathogenesis, 78  
   pathologic features, 78  
   prognosis and treatment, 81  
 Baller-Gerold syndrome, 39  
 B-cell lymphoma  
   unclassifiable with intermediate  
     features, 258–259  
     clinical features, 258  
     genetic features, 258  
     morphologic and immunophenotypic  
     features, 258  
     prognosis and treatment, 259  
   *see also* high-grade B-cell lymphoma  
     (HGBL); large B-cell lymphoma  
     (LBCL) with *IRF4*  
     rearrangement.  
 Bernard-Soulier syndrome, 55  
 blastic plasmacytoid dendritic cell  
   neoplasm (BPDCN), 196–197  
   ancillary diagnostic testing, 196  
   clinical context, 196  
   knowledge gaps, 197  
   microscopic features, 196  
   prognosis and treatment, 197  
   proposed pathogenesis, 196  
   “blood islands”, 1  
 Bloom syndrome, 37, 39, 175, 209  
 B-lymphoblastic leukemia/lymphoma  
   (B-ALL/B-LBL), 208–220  
   cytogenetic testing, 108–109  
   differential diagnosis, 128, 134, 238  
   flow cytometry testing, 101–103  
   not otherwise specified (B-ALL/LBL,  
     NOS), 208–215  
     clinical features, 209  
     differential diagnosis, 213  
     epidemiology, 209  
     etiology, 209  
     genetic features, 213  
     immunophenotype, 213  
     morphological features, 209–213  
     prognosis and treatment, 213–215  
   prognostic parameters, 222  
   with recurrent genetic abnormalities,  
     215–220  
     *BCR-ABL1*, 215  
     *BCR-ABL1*-like, 216–220  
     *DUX4* rearrangements and *ERG*  
     deletion, 220  
     *ETV6-RUNX1*, 215  
     with hyperdiploidy, 215  
     with hypodiploidy, 216  
     *iAMP21*, 220  
     *IL3-IGH*, 216  
     *KMT2A*-rearranged, 215  
     *TCF3-PBX1*, 216  
   bone marrow biopsy, standard site for, 2  
   bone marrow failure syndromes, 25  
     acquired aplastic anemia, 43–46  
     acquired pure red blood cell aplasia  
       (PRCA), 28  
     associated with multi-lineage cytopenias  
       or pancytopenia, 36–46  
     associated with single-lineage  
       cytopenias, 25–36  
     congenital amegakaryocytic  
       thrombocytopenia (CAMT),  
       33–35  
     congenital dyserythropoietic anemia  
       (CDA), 28  
     cyclic neutropenia (CyN), 32–33  
     Diamond-Blackfan anemia (DBA),  
       25–28  
     differential diagnosis, 153, 189  
     dyskeratosis congenita (DKC), 39–41  
     Fanconi anemia (FA), 36–39  
     neutropenias, 30  
     severe congenital neutropenia (SCN),  
       28–32

## Index

- bone marrow failure syndromes (cont.)  
 Shwachman-Diamond syndrome (SDS), 42–43  
 thrombocytopenia-absent radii (TAR), 35–36  
*see also under individual conditions.*  
 bone marrow macrophage accumulation in storage disease, 316  
 bone marrow transplant  
 CAMT, 34  
 Chédiak-Higashi syndrome, 56  
 LPD-associated PIDs, 298  
 bowel disease, inflammatory (IBD), 302  
 Burkitt lymphoma/leukemia (BL), 235–238, 296  
 clinical features, 237  
 differential diagnosis, 238  
 epidemiology, 235–236  
 endemic variant, 235  
 immunodeficiency-associated variant, 236  
 sporadic variant, 235  
 etiology, 236  
 genetic features, 238  
 immunophenotype, 238  
 morphologic features, 237–238  
 pathogenesis, 236  
 prognosis and treatment, 238  
 Burkitt-like lymphoma with 11q aberration (BL, 11q), 259–261  
 differential diagnosis, 238  
 Castleman disease (CD), 73–75  
 clinical features, 73  
 cytogenetic findings, 75  
 differential diagnosis, 74, 80  
 immunophenotype, 74  
 morphological variants, 73  
 pathogenesis, 73–74  
 pathologic features, 74  
 prognosis and treatment, 75  
 cat-scratch disease, 87–89  
 clinical features, 87  
 differential diagnosis, 89  
 pathogenesis, 89  
 pathologic features, 89  
 prognosis, 89  
 celiac disease, relationship with T-cell lymphomas, 272  
 Chédiak-Higashi syndrome, 55–56  
 clinical features, 55  
 differential diagnosis, 56  
 knowledge gaps, 56  
 microscopic features, 56  
 pathogenesis, 56  
 prognosis, 56  
 chromosomal microarray (CMA), 108  
 chronic eosinophilic leukemia (CEL), 143–144  
 chronic granulomatous disease (CGD), 316  
 chronic myeloid leukemia (CML), 130–134  
 accelerated phase, 131  
 ancillary diagnostic testing, 132–133  
 blast phase, 132  
 chronic phase, 130–131  
 clinical features, 130  
 differential diagnosis, 62, 123, 127, 134, 143, 144, 165  
 genetics, 133–134  
 knowledge gaps, 134  
 microscopic features, 130–132  
 phases of progression, 133  
 prognosis and management, 134  
 chronic myelomonocytic leukemia (CMML), differential diagnosis, 123  
 chronic neutrophilic leukemia (CNL), 142–143  
 ancillary diagnostic testing, 143  
 clinical features, 143  
 diagnostic criteria, 142  
 differential diagnosis, 134, 143–144  
 genetics, 143  
 knowledge gaps, 143  
 microscopic features, 143  
 prognosis, 143  
 classic Hodgkin lymphoma (CHL), 285–289  
 clinical features, 285  
 differential diagnosis, 248, 266, 288–289  
 epidemiology, 285  
 genetic features, 287  
 immunophenotype, 287  
 incidence in HIV patients, 298  
 morphologic features, 285–289  
 lymphocyte-depleted (LD) subtype, 286  
 lymphocyte-rich (LR) subtype, 286  
 mixed cellularity (MC) subtype, 286  
 nodular sclerosis (NS) subtype, 285  
 post-transplant lymphoproliferative disorders (CHL-PTLDs), 300  
 prognosis and treatment, 289  
 classification, 9, 78–80, 112, 114, 117, 155–156, 163, 168–169, 199, 203, 208, 220, 224–225, 235, 331  
 cobalamin, *see* vitamin B12 and folate deficiency  
 common variable immunodeficiency (CVID), 296  
 congenital amegakaryocytic thrombocytopenia (CAMT), 33–35  
 ancillary diagnostic testing, 33  
 clinical features, 33  
 differential diagnosis, 34, 153  
 genetics, 33–34  
 knowledge gaps, 35  
 microscopic features, 33  
 prognosis, 34  
 congenital dyserythropoietic anemia (CDA), 12–14, 28  
 clinical features, 12  
 differential diagnosis, 13–14  
 pathogenesis, 13  
 pathologic features, 13, 14  
 prognosis, 14  
 congenital sideroblastic anemia (CSA), 15–16  
 clinical features, 16  
 pathogenesis, 16  
 pathologic features, 16  
 prognosis and treatment, 16  
 constitutional anemia and hemoglobinopathy, 9–17  
 congenital dyserythropoietic anemia (CDA), 12–14  
 congenital sideroblastic anemia (CSA), 15–16  
 glucose-6-phosphate dehydrogenase (G6PD) deficiency, 16–17  
 sickle cell anemia, 11–12  
 thalassemias, 9–11  
*see also under individual conditions.*  
 cutaneous T-cell lymphoma (CTCL), differential diagnosis, 325  
 cyclic neutropenia (CyN), 32–33  
 ancillary diagnostic testing, 32  
 clinical features, 32  
 differential diagnosis, 32  
 genetics, 32  
 knowledge gaps, 33  
 microscopic features, 32  
 most common causes of death, 32  
 prognosis and management, 32  
 cystic fibrosis, differential diagnosis for SDS, 43  
 cytogenetics, 107–114  
 DS-ALL/AML, 114  
 FA, 114  
 hematologic neoplasms, 107  
 chromosomal abnormalities, 108, 114  
 lymphoid neoplasms, 108–112  
 myeloid neoplasms, 112, 113  
 cytokines, role in hematopoiesis, 2  
 cytomegalovirus (CMV) infection, 92–93  
 clinical features, 92  
 differential diagnosis, 93, 123, 153  
 immunophenotype, 93  
 pathogenesis, 92  
 pathologic features, 92  
 prognosis, 93  
 dendritic cells, identification of, 310  
 dermatopathic lymphadenopathy, 77–78  
 clinical features, 77

- differential diagnosis, 78  
 pathogenesis, 78  
 pathologic features, 78  
 prognosis and treatment, 78
- Diamond-Blackfan anemia (DBA), 25–28, 38  
 ancillary diagnostic testing, 27  
 association with t-MNs, 175  
 clinical features, 25  
 differential diagnosis, 28  
 genetics, 27–28  
 knowledge gaps, 28  
 microscopic features, 25  
 principal causes of death, 28  
 prognosis and treatment, 28
- Dianzani autoimmune lymphoproliferative disease, differential diagnosis, ALPS, 80
- diffuse large B-cell lymphoma not otherwise specified (DLBCL, NOS), 238–243  
 clinicopathologic features of GCB type and ABC type, 243  
 differential diagnosis, 238, 243  
 epidemiology, 238  
 etiology, 239  
 genetic features, 242–243  
 immunophenotype, 241  
 morphologic features, 240–241  
 prognosis and treatment, 243
- DNA ligase IV, 39, 41
- Döhle bodies, 55
- Down syndrome (DS)  
 acute leukemia, cytogenetic testing, 114  
 association with t-MNs, 175  
 comparison of megakaryocytic neoplasms, 186  
 increased risk for B-ALL, 209, 219  
*see also* myeloid leukemia associated with Down syndrome (ML-DS); transient abnormal myelopoiesis (TAM).
- dyskeratosis congenita (DKC), 28, 38, 39–41  
 ancillary diagnostic testing, 40  
 clinical features, 39–40  
 differential diagnosis, 28, 41, 153  
 genetics, 40–41  
 knowledge gaps, 41  
 microscopic features, 40  
 prognosis and treatment, 41
- elliptocytosis, hereditary, *see* hereditary elliptocytosis (HE).
- enteropathy-associated T-cell lymphoma (EATL), differential diagnosis, 272
- Epstein-Barr virus (EBV)  
 association with lymphomas in HIV patients, 298  
 clinical features, 89  
 differential diagnosis, 123, 153, 324  
 EBV-positive T-cell lymphoproliferative disorders of childhood, 279–283  
*see also* hydroa vacciniforme-like lymphoproliferative disorder (HVLDP); syste.  
 HLH-associated, 325  
 in immunodeficiency-associated BL cases, 236  
 and methotrexate-associated LPDs, 302  
 NK-cell leukemia and, 281  
 pathogenesis, 89  
 PIDs and, 296  
 prognosis and management, 92  
 PTLD and, 299  
 role in BL etiology/pathogenesis, 237  
 Erdheim-Chester disease, pediatric, 338  
 erythropoiesis, embryonic, 1  
 essential thrombocythemia (ET), 137–139  
 ancillary diagnostic testing, 139  
 clinical features, 137  
 diagnostic criteria, 137  
 post-essential thrombocythemia myelofibrosis, 137  
 differential diagnosis, 136, 139  
 genetics, 139  
 knowledge gaps, 139  
 microscopic features, 137–138  
 prognosis and management, 139
- Ewing sarcoma, 231, 232
- extranodal NK-/T-cell lymphoma (ENKTCL)  
 differential diagnosis, 283  
 nasal type, 271–272  
 clinical features, 271  
 differential diagnosis, 272  
 epidemiology, 271  
 etiology, 271  
 genetic features, 272  
 immunophenotype, 272  
 morphologic features, 271  
 prognosis and treatment, 272
- familial platelet disorder, 175
- Fanconi anemia (FA), 36–39  
 ancillary diagnostic testing, 37  
 association with t-MNs, 175  
 clinical features, 36–37  
 cytogenetic testing, 114  
 differential diagnosis, 28, 34, 36, 38–39, 41, 153  
 FA-related MDS, 37  
 genetics, 37–38  
 knowledge gaps, 39  
 microscopic features, 37
- prognosis and treatment, 39
- fava beans, 16
- florid follicular hyperplasia, 94, 95, 298, 299
- flow cytometry, 97–107  
 ALPS, 103  
 detection of MRD in B-ALL, 101–103  
 general principles, 97–98  
 immunophenotypic markers, 100  
 immunophenotyping panels, 100–101  
 lineage-specific cell maturation, 98–100  
 MDS, 106  
 PNH, 103  
 sample considerations, 97–98  
 specialised applications, 101–107  
 technical considerations, 98
- fluorescence in situ hybridization (FISH), 107, 108
- follicular hyperplasia (FH), 67, 296  
 clinical features, 67  
 cortical, 296  
 differential diagnosis, 249  
 immunophenotype, 67  
 pathologic features, 67  
 prognosis and treatment, 67  
 fungal infections, 85–87, 93  
 clinical features, 85  
 differential diagnosis, 86  
 pathogenesis, 85  
 pathologic features, 85–86  
 prognosis, 87
- germline predisposition syndromes, differential diagnosis, 189
- giant lymph node hyperplasia, *see* Castleman disease (CD).
- giant platelet syndromes, 55
- glucose-6-phosphate dehydrogenase (G6PD) deficiency, 16–17  
 clinical features, 16, 17  
 pathogenesis, 17  
 pathologic features, 17  
 prognosis and management, 17
- granulomatous disease and manifestations, 316
- gray platelet syndrome, 55
- Heinz bodies, 11, 17
- Helicobacter pylori, and absorption of dietary iron, 18
- hematologic neoplasms, ancillary tests, cytogenetics, 107–108, 114
- hematopoiesis, 1  
 adult, 2  
 development of, 1–2  
 embryonic and fetal, 1–2  
 neonatal and childhood, 2  
 normal BM in children, 3–4  
 the process, 2  
 regulation, 2–3



## Index

- hematopoietic stem cell transplantation (HSCT), 11  
 ALPS, 81  
 AML, 165  
 CDA, 14  
 CSA, 16  
 HSTCL, 275  
 HVLPD, 283  
 osteopetrosis, 65  
 post-transplant disorders, 296, 299  
 post-transplant therapies, 61  
 sickle cell disease, 12  
 thalassemia patients, 11  
 hematopoietic stem cells (HSCs), in fetal development, 1, 3  
 hemoglobin, function and structure, 9  
 hemolytic anemia, G6PD deficiency and, 16  
 hemophagocytic lymphohistiocytosis (HLH), 320–326  
 bone marrow, 322  
 central nervous system, 325  
 cytogenetic and molecular genetic features, 326  
 diagnostic criteria, 320  
 differential diagnosis, 142, 322–324, 325  
 liver, 322–324  
 lymph node, 324–325  
 macrophage activation and the hemophagocytic syndromes, 320–321  
 morphology, 321  
 prognosis and treatment, 326  
 skin, 325  
 spleen, 325  
 hemophagocytic syndrome, 272, 277–278, 280, 296  
 hepatosplenic T-cell lymphoma (HSTCL), 272–275, 302  
 clinical features, 273  
 epidemiology, 273  
 genetic features, 275  
 immunophenotype, 274  
 morphologic features, 274  
 prognosis and treatment, 275  
 hereditary elliptocytosis (HE), 15  
 clinical features, 15  
 differential diagnosis, 15  
 pathogenesis, 15  
 pathologic features, 15  
 prognosis, 15  
 hereditary erythroblastic multinuclearity with positive acidified serum test (HEMPAS), *see* congenital dyserythropoietic anemia (CDA).  
 hereditary pyropoikilocytosis (HPP), 15  
 hereditary spherocytosis (HS), 14–15  
 clinical features, 14  
 parvovirus B19 infection and, 14  
 pathogenesis, 14  
 pathologic features, 14  
 prognosis and treatment, 15  
 high-grade B-cell lymphoma (HGBL) with gene rearrangements, 254–255  
 clinical features, 255  
 cytogenetic features, 255  
 differential diagnosis, 238  
 expression of protein markers, 257  
 immunophenotype, 255  
 morphologic features, 255  
 partner genes, 257  
 prognosis, 255  
 not otherwise specified (HGBL-NOS), 255–258  
 differential diagnosis, 238  
 genetic features, 258  
 immunophenotype, 257  
 morphological features, 257  
 histiocytes  
 antibodies and enzymes most informative for, 310  
 changing appearance and phenotype, 310  
 functional defects of, 315  
 non-neoplastic accumulation, *see* non-neoplastic accumulation of histiocytes.  
 origins and variety of, 307–308  
 selected antibodies informative for, 310  
 use of the term, 307  
 histiocytic inflammatory neoplasms/lesions, 330–347  
 aggressive/atypical histiocytic neoplasms, 344–347  
 histiocytic sarcoma, 344–346  
 Langerhans cell sarcoma (LSC, 344  
 malignant histiocytic neoplasms in children, 344  
 post-leukemic/lymphoma histiocytic neoplasms, 346–347  
 ALK-positive histiocytosis, 338  
 histiocytic lesions/neoplasms, 330  
 juvenile xanthogranulomas (JXG), 335–338  
 Langerhans cell histiocytosis (LCH), 331–335  
 mixed histiocytosis, 341  
 pediatric Erdheim-Chester disease, 338  
 Rosai-Dorfman-Destombes disease (RDD), 339–341  
*see also under individual conditions.*  
 histiocytic necrotizing lymphadenitis, *see* Kikuchi-Fujimoto disease (KFD).  
 histiocytic sarcoma, 344–346  
 differential diagnosis, 346  
 immunophenotype, 345  
 morphology, 345  
 prognosis and treatment, 346  
*see also* malignant histiocytic neoplasms.  
 histiocytosis  
 ALK-positive, 338  
 mixed, *see* mixed histiocytosis.  
*see also* Langerhans cell histiocytosis (LCH).  
 histoplasmosis, 61  
 Hodgkin lymphoma (HL), 285–294, 296  
 classic HL (CHL), 285–289  
 differential diagnosis, 78, 142, 346  
 immunophenotype, 298  
 nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), 289–294  
*see also under individual conditions.*  
 Holt-Oram syndrome, 36, 39  
 Howell-Jolly bodies, 11  
 human immunodeficiency virus (HIV), 59–61, 93–94, 153  
 clinical features, 60, 93  
 differential diagnosis, 94, 153  
 HIV-associated lymphoproliferations, 298  
 pathogenesis, 60, 94  
 pathologic features, 61, 94  
 prognosis, 61, 94  
 relationship with immunodeficiency-associated BL, 236  
 hydroa vacciniforme-like lymphoproliferative disorder (HVLPD), 279, 281, 283  
 clinical features, 281  
 differential diagnosis, 283  
 epidemiology, 281  
 genetic features, 283  
 immunophenotype, 283  
 morphologic features, 281  
 prognosis and treatment, 283  
 hyper-IgM syndrome (HIGM), 296  
 idiopathic thrombocytopenic purpura (ITP), 59  
 clinical features, 59  
 differential diagnosis, 34, 59  
 pathogenesis, 59  
 pathological features, 59  
 prognosis and treatment, 59  
 iliac crest, standard site for BM biopsy, 2  
 immune system, 5  
 immunodeficiency, 296  
 immunodeficiency and altered immunity associated histiocytic collections, 315  
 immunodeficiency-associated lymphoproliferative disorders

- HIV-associated lymphoproliferations, 298  
 other iatrogenic disorders, 302  
 post-transplant lymphoproliferative disorder (PTLD), 299–301  
 primary immune disorders (PIDs), 296–298  
*see also under individual conditions.*  
 immunoglobulin, as treatment for ITP, 59  
 immunohistochemistry (IHC), 107  
   applications, 107  
   general principles, 107  
   strengths and limitations, 107  
   tissue conditions, 107  
 immunophenotyping panels  
   B-cell panels, 100  
   myeloid/monocytoid panels, 101  
   surveillance panels, 100  
   T-cell panels, 101  
 incontinentia pigmenti, 41  
 indolent T-lymphoblastic proliferations, 224  
 infectious lymphadenopathy, 84–95  
   cat-scratch disease, 87–89  
   cytomegalovirus infection, 92–93  
   fungal infection, 85–87  
   human immunodeficiency virus (HIV), 93–94  
   infectious mononucleosis, 89–92  
   mycobacteria infection, 84–85  
   toxoplasmosis lymphadenitis, 94–95  
*see also under individual conditions.*  
 infectious mononucleosis (IM), 89–92, 296  
   clinical features, 89  
   differential diagnosis, 91  
   immunophenotype, 90–91  
   pathogenesis, 89  
   pathologic features, 89–90  
   prognosis and management, 92  
 inflammatory bowel disease (IBD), 302  
 inherited leukocyte disorders, 52–57  
   Alder-Reilly anomaly, 56–57  
   Chédiak-Higashi syndrome, 55–56  
   May-Hegglin anomaly, 54–55  
   Pelger-Huët anomaly, 52–53  
*see also under individual conditions.*  
 iron deficiency anemia (IDA)  
   as cause of elliptocytosis, 15  
   clinical features, 17  
   differential diagnosis, 18  
   pathogenesis, 17–18  
   pathological features, 18  
   prognosis and treatment, 18  
 juvenile myelomonocytic leukemia (JMML), 121–124  
   ancillary diagnostic testing, 122  
   clinical features, 121  
   diagnostic criteria, 121  
   differential diagnosis, 62, 123, 124, 134  
   genetics, 122–123  
   knowledge gaps, 124  
   microscopic features, 121  
   prognosis and treatment, 124  
 juvenile xanthogranulomas (JXG), 335–338  
   clinical nomenclature, 335  
   cytogenetic and molecular genetic features, 338  
   differential diagnosis, 338  
   immunophenotype, 337  
   morphology, 337  
 karyotyping, 107, 109, 113, 238  
 Kikuchi-Fujimoto disease (KFD), 68, 69, 70, 71, 73, 92, 93  
   clinical features, 68  
   differential diagnosis, 69  
   ALPS, 80  
   immunophenotype, 69  
   pathologic features, 69  
   prognosis, 70  
 Kimura disease, 76  
   clinical features, 76  
   differential diagnosis, 76  
   pathologic features, 76  
   prognosis and treatment, 76  
 Langerhans cell histiocytosis (LCH), 331–335  
   cytogenetic and molecular genetic features, 334  
   differential diagnosis, 78, 335  
   immunophenotype, 332–334  
   morphology, 332  
   prognosis and treatment, 335  
 Langerhans cell hyperplasia  
   differential diagnosis, 312  
   immunophenotype, 312  
   morphology, 312  
   skin and lymph node, 312  
 Langerhans cell sarcoma (LCS), 344  
 Langerhans cells (LC), 312  
 large B-cell lymphoma (LBCL) with *IRF4* rearrangement, 249–252  
   clinical features, 251  
   differential diagnosis, 249  
   epidemiology, 251  
   genetic features, 252  
   immunophenotype, 251  
   morphologic features, 251  
   prognosis and treatment, 252  
 leukemoid reaction and granulocyte colony stimulating factor effect, 61–62  
   clinical features, 61  
   differential diagnosis, 62  
   pathogenesis, 61  
   pathologic features, 61  
   prognosis and treatment, 62  
   leukemoid reactions, differential diagnosis, 134, 143  
   leukocytic disorders, inherited, *see* inherited leukocyte disorders.  
 Li-Fraumeni syndrome, 209, 216  
 liver, role in fetal hematopoiesis, 2  
 lymph nodes  
   anatomy and function, 5–7  
   benign enlargement, 67  
   *see also* non-infectious lymphadenopathy.  
   cortex, 5–6  
   gross anatomy, 5  
   lymph node sinuses, 7  
   major cell elements and their immunophenotype, 7  
   medulla, 7  
   paracortex, 6  
   structure and function, 5–7  
   vascular structure, 7  
 lymphoblastic lymphoma, 298  
 lymphoid hyperplasia, 81, 82  
   clinical features, 81  
   pathologic features, 82  
   prognosis and treatment, 82  
 lymphomatoid granulomatosis (LG), 296  
   differential diagnosis, 272  
 lymphomatoid papulosis (LyP), 275  
   clinical features, 275  
   genetic features, 275  
   pathologic features, 275  
   prognosis, 275  
 lymphoproliferation, 296  
   in HIV infection, 298  
 lymphoproliferative disorders (LPDs)  
   associated PIDs, 296–298  
   *see also under* primary immune disorders (PIDs).  
   *see also* primary cutaneous CD30+ T-cell lymphoproliferative disorders (LPD).  
 macrocytosis, causes of, 20, 153  
 macrophage activation syndrome (MAS), diagnostic criteria, 321  
 macrophages, identification of, 310  
 malaria, relationship to thalassemias, 9  
 malignant histiocytic neoplasms  
   in children, 344  
   cytogenetic and molecular genetic features, 346  
 marble bone disease, *see* osteopetrosis.  
 mature B-cell non-Hodgkin neoplasms, 235–261  
   B-cell lymphoma, unclassifiable with intermediate features, 258–259

## Index

- mature B-cell (cont.)  
 Burkitt lymphoma/leukemia (BL), 235–238, 296  
 Burkitt-like lymphoma with 11q aberration (BLL, 11q), 259–261  
 cytogenetic testing, 109–112  
 diffuse large B-cell lymphoma not otherwise specified (DLBCL, NOS), 238–243  
 high-grade B-cell lymphoma (HGBL) with gene rearrangements, 254–255  
 not otherwise specified (HGBL-NOS), 255–258  
 immunophenotypic markers, 236  
 large B-cell lymphoma (LBCL) with *IRF4* rearrangement, 249–252  
 pediatric-type follicular lymphoma (PTFL), 248–249  
 pediatric-type marginal zone lymphoma (PTMZL), 253–254  
 primary mediastinal large B-cell lymphoma (PMBL), 244–246  
 T-cell/histiocyte rich large B-cell lymphoma (THRLBCL), 246–248  
 workup of non-Hodgkin lymphomas, 237  
*see also under individual conditions.*  
 mature T-cell and NK-cell non-Hodgkin lymphomas, 263–283  
 anaplastic large cell lymphoma (ALCL), ALK-negative, 266, 269  
 anaplastic large cell lymphoma (ALCL), ALK-positive, 263–266  
 cytogenetic testing, 112  
 EBV-positive T-cell lymphoproliferative disorders of childhood, 279–283  
*see also* hydroa vacciniforme-like.  
 extranodal NK-/T-cell lymphoma (ENKTCL), nasal type, 271–272  
 hepatosplenic T-cell lymphoma (HSTCL), 272–275, 302  
 lymphomatoid papulosis (LyP), 275  
 peripheral T-cell lymphoma (PTCL), 263  
 not otherwise specified (PTCL-NOS), 269–271  
 primary cutaneous anaplastic large cell lymphoma (C-ALCL), 275–276  
 primary cutaneous  
 CD4+ small/medium T-cell lymphoproliferative disorder (PCS/M-TCLPD), 278–279  
 primary cutaneous CD30+ T-cell lymphoproliferative disorders (LPDs), 275–278  
 subcutaneous panniculitis-like T-cell lymphoma (SPTCL), 276–278  
*see also under individual conditions.*  
 May-Hegglin anomaly, 54–55  
 clinical features, 54  
 differential diagnosis, 55  
 knowledge gaps, 55  
 microscopic features, 55  
 pathogenesis, 55  
 prognosis, 55  
 megaloblastic anemia  
 as cause of elliptocytosis, 15  
 role of vitamin B12 and folate deficiency, 19  
 melanoma, differential diagnosis, 266  
 metastatic carcinoma, differential diagnosis, 266  
 metastatic tumor in the BM  
 Ewing sarcoma, 231–232  
 laboratory findings  
 bone marrow changes, 227–229  
 peripheral blood changes, 227  
 nasopharyngeal carcinoma (NPC), 233  
 neuroblastoma, 229  
 osteosarcoma, 232  
 rare solid tissue tumors, 232–233  
 retinoblastoma, 232  
 rhabdomyosarcoma (RMS), 229–231  
 methotrexate-associated LPDs, EBV and, 302  
 mixed histiocytosis, 341  
 differential diagnosis, 341  
 mixed-phenotype acute leukemia (MPAL), 201–203  
 diagnostic features of subtypes, 201–202  
 epidemiology, 201  
 genetic features, 202  
 lineage assignment, WHO requirements, 202  
 lineage markers, 201  
 pathologic features, 201  
 prognosis, 203  
 terminology, 201  
 molecular genetics, 114–118  
 molecular assays, summary, 115–118  
 sample considerations, 114–115  
 monomorphic post-transplant lymphoproliferative disorders (M-PTLDs), 300  
 mononuclear phagocytic system (MPS), 307  
 mononucleosis, infectious, *see* infectious mononucleosis (IM).  
 Montreal platelet syndrome, 55  
 myasthenia gravis (MG), association with lymphoid hyperplasia, 81  
 mycobacteria infection  
 clinical features, 84  
 differential diagnosis, 85  
 pathogenesis, 84  
 pathologic features, 84  
 prognosis and treatment, 85  
 Mycobacterium avium-intracellulare (MAI), 61  
 myelodysplasia, as cause of elliptocytosis, 15  
 myelodysplasia-related changes, acute myeloid leukemia with (AML-MRC) *see under* acute myeloid leukemia (AML).  
 myelodysplastic syndromes (MDS), 148–153  
 ancillary diagnostic testing, 151–152  
 clinical features, 148  
 cytogenetic testing, 113  
 diagnostic criteria  
 2016 revision, **149**  
 proposed, **148**  
 differential diagnosis, 152–153  
 Fanconi anemia-related, 37  
 flow cytometry testing, 106  
 genetics, 152  
 knowledge gaps, 153  
 MDS with excess blasts, 150–151  
 microscopic features, 148  
 prognosis and treatment, 148, 153  
 refractory anemia with excess blasts in transformation (RAEB-T), 151  
 refractory cytopenia of childhood (RCC), 148–150  
 risk of development  
 for aplastic anemia patients, 46  
 for FA patients, 39  
 for leukemoid reaction patients, 62  
 for SCN patients, 31  
 for SDS patients, 42  
 unclassifiable (MDS-U), 151  
 myeloid hyperplasia, key features, **63**  
 myeloid leukemia associated with Down syndrome (ML-DS), 184–186  
 clinical features, 184  
 differential diagnosis, 186  
 genetic features, 186  
 immunophenotype, 186  
 pathologic features, 185  
 prognosis and treatment, 186  
 myeloid neoplasms, ancillary tests, cytogenetics, 112, 113  
 myeloid neoplasms with germline predisposition, 189, **194**  
 adapted from WHO 2016, **190–192**  
 clinical features, 189  
 differential diagnosis, 189  
 emerging, **193–194**  
 genetics, 189  
 immunophenotype, 189

- pathologic features, 189
- prognosis and treatment, 189
- myeloid sarcoma (MS), 181–183
  - clinical features, 181
  - differential diagnosis, 182, 346
  - genetic features, 182
  - immunophenotype, 182
  - pathologic features, 181
  - prognosis, 183
- myeloid/lymphoid neoplasms with
  - eosinophilia and gene rearrangement, 126–128
  - ancillary diagnostic testing, 127
  - clinical features, 126
  - diagnostic criteria, 126
  - differential diagnosis, 127–128
  - genetics, 127
  - knowledge gaps, 128
  - microscopic features, 126–127
  - prognosis and treatment, 128
- myeloproliferative neoplasms, 130–144
  - chronic eosinophilic leukemia (CEL), 143–144
  - chronic myeloid leukemia (CML), 130–134
  - chronic neutrophilic leukemia (CNL), 142–143
  - essential thrombocythemia (ET), 137–139
  - polycythemia vera, 134–137
  - primary myelofibrosis (PMF), 139–142
  - see also under individual conditions.*
- Naegeli-Franceschetti-Jadassohn
  - syndrome/dermatopathy pigmentosa reticularis, 41
- nasopharyngeal carcinoma (NPC), 233
- natural killer (NK)-cells, 263
- neoplastic lymphoid proliferation with
  - follicular pattern, differential diagnosis, 249
- neuroblastoma, 229
- neurofibromatosis type 1, 175
- neutropenias
  - causes of acquired neutropenia in children, 31
  - see also* cyclic neutropenia (CyN); severe congenital neutropenia (SCN).
- Nijmegen breakage syndrome (NBS), 37, 39, 296
- NK-lymphoblastic leukemia/lymphoma (NK-ALL/LBL), 225
- nodular lymphocyte predominant
  - Hodgkin lymphoma (NLPHL), 289–294
  - clinical features, 289
  - differential diagnosis, 248, 293
  - genetic features, 293
- immunophenotype, 291–293
- morphologic features, 291
- prognosis, 294
- nodular lymphoid hyperplasia, 296
- non-Hodgkin lymphoma (NHL)
  - adult vs pediatric, 235
  - differential diagnosis, 142, 266
  - immunophenotype, 298
  - incidence in HIV patients, 298
  - workup of, 237
- non-infectious lymphadenopathy, 67–82
  - autoimmune lymphoproliferative syndrome (ALPS), 78–81
  - Castleman disease (CD), 73–75
  - dermatopathic lymphadenopathy, 77–78
  - Kikuchi-Fujimoto disease (KFD), 68–70
  - Kimura disease, 76
  - lymphoid hyperplasia, 81–82
  - progressive transformation of germinal centers (PTGCs), 67–68
  - reactive follicular hyperplasia (FH), 67
  - sarcoidosis, 76–77
  - systemic lupus erythematosus (SLE), 70–73
  - see also under individual conditions.*
- non-neoplastic accumulation of
  - histiocytes, 312–319
  - bone marrow macrophage accumulation in storage disease, 316
  - functional defects of histiocytes, 315
  - granulomatous disease and manifestations, 316
  - immunodeficiency and altered immunity associated histiocytic collections, 315
  - Langerhans cell hyperplasia, skin and lymph node, 312
  - tumor-associated macrophage accumulations, 317–319
  - xanthogranulomatous inflammation, 313–315
- non-neoplastic lesions, 296
- non-neoplastic lymphoid proliferation
  - with follicular pattern, differential diagnosis, 249
- osteopetrosis, 63–65, 142
  - clinical features, 63–64
  - pathogenesis, 64
  - pathologic features, 65
  - prognosis and management, 65
- osteosarcoma, 232
- Pappenheimer bodies, 11, 16
- paracortical hyperplasia, 296
- paroxysmal nocturnal hemoglobinuria (PNH), 22–23
- clinical features, 22
- flow cytometry testing, 103, 152
- pathogenesis, 22
- pathologic features, 23
- prognosis and management, 23
- parvovirus B19 infection, differential diagnosis, 123, 153
- parvovirus B19 infection-produced red cell aplasia, 21–22
  - clinical features, 21
  - differential diagnosis, 21, 123, 153
  - pathogenesis, 21
  - pathologic features, 21
  - prognosis and management, 22
- Pearson syndrome, 151
  - association with CSA, 16
  - differential diagnosis for DBA, 28
  - differential diagnosis for SDS, 43
- pediatric Erdheim-Chester disease, 338
- pediatric nodal marginal zone lymphoma (PNMZL), 253
- pediatric-type follicular lymphoma (PTFL), 248–249
  - clinical features, 248
  - differential diagnosis, 249, 251
  - epidemiology, 248
  - genetic features, 249
  - immunophenotype, 249
  - morphologic features, 248–249
  - prognosis and treatment, 249
- pediatric-type marginal zone lymphoma (PTMZL), 253–254
  - differential diagnosis, 253
  - epidemiology, 253
  - genetic features, 253
  - immunophenotype, 253
  - morphologic features, 253
  - prognosis and treatment, 253
- Pelger-Huët anomaly, 52–53
  - ancillary diagnostic testing, 53
  - clinical features, 52
  - differential diagnosis, 52–53
  - knowledge gaps, 53
  - microscopic features, 52
  - pathogenesis, 52
  - prognosis, 53
- peripheral T-cell lymphoma (PTCL), 263, 296
  - differential diagnosis, 80, 248
  - not otherwise specified (PTCL-NOS), 269–271
    - clinical features, 269
    - differential diagnosis, 271
    - epidemiology, 269
    - genetic features, 271
    - immunophenotype, 270
    - morphologic features, 270
    - prognosis, 271
  - phlebotomy, in management of CDA, 14



## Index

- poikiloderma, 41  
 polycythemia vera (PV), 134–137  
   ancillary diagnostic testing, 135  
   clinical features, 134–135  
   diagnostic criteria, 135  
   post-PV MF, 135  
   differential diagnosis, 136  
   genetics, 136  
   knowledge gaps, 137  
   microscopic features  
     “Masked” & Overt polycythemia, 135  
   post-PV MF, 135  
   prognosis and treatment, 136  
 polymorphic lymphoid infiltrates, 296  
 polymorphic post-transplant lymphoproliferative disorders (P-PTLDs), 300  
 post-essential thrombocythemia myelofibrosis, diagnostic criteria, 137  
 post-leukemic/lymphoma histiocytic neoplasms, 346–347  
   cytogenetic and molecular genetic features, 346  
   differential diagnosis, 346  
   immunophenotype, 346  
   morphology, 346  
   prognosis, 347  
 post-polycythemia vera myelofibrosis (post-PV MF), 135  
 post-transplant lymphoproliferative disorder (PTLD), 299–301  
   clinical features, 299  
   epidemiology, 299  
   etiology, 299  
   morphologic features, 299–301  
     classic Hodgkin lymphoma disorders (CHL-PTLDs), 300  
     monomorphic disorders (M-PTLDs), 300  
     non-destructive PTLDs, 299  
     polymorphic disorders (P-PTLDs), 300  
   prognosis and treatment, 301  
 precursor lymphoid neoplasms, 208  
   B-lymphoblastic leukemia/lymphoma, 208–220  
     classification, 208  
     NK-lymphoblastic leukemia/lymphoma, 225  
     T-Lymphoblastic leukemia/lymphoma, 220–224  
     *see also under individual conditions.*  
   primary cutaneous anaplastic large cell lymphoma (C-ALCL), 275–276  
     clinical features, 275–276  
     differential diagnosis, 276  
     genetic features, 276  
     immunophenotype, 276  
     morphologic features, 276  
     prognosis, 276  
   primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCS/M-TCLPD), 278–279  
     clinical features, 278  
     genetic features, 279  
     immunophenotype, 279  
     morphologic features, 278  
     prognosis and treatment, 279  
   primary cutaneous CD30+ T-cell lymphoproliferative disorders (LPDs), 275–278  
     lymphomatoid papulosis (LyP), 275  
     primary cutaneous anaplastic large cell lymphoma (C-ALCL), 275–276  
     subcutaneous panniculitis-like T-cell lymphoma (SPTCL), 276–278  
     *see also under individual conditions.*  
   primary cutaneous  $\gamma\delta$  T-cell lymphoma, differential diagnosis, 283  
   primary immune disorders (PIDs), 296  
     LPD-associated, 296–298  
   primary immune disorders (PIDs), LPD-associated  
     clinical features, 296, 297  
     genetic features, 298  
     immunophenotype, 298  
     morphologic features, 296–298  
     prognosis and treatment, 298  
   primary mediastinal large B-cell lymphoma (PMBL), 244–246  
     clinical features, 244  
     differential diagnosis, 245, 246  
     epidemiology, 244  
     genetic features, 244  
     immunophenotype, 244  
     morphologic features, 244  
     prognosis and treatment, 245  
   primary myelofibrosis (PMF), 139–142  
     ancillary diagnostic testing, 141  
     clinical features, 139  
     diagnostic criteria, 140  
     differential diagnosis, 142  
     extramedullary disease, 140  
     genetics, 142  
     knowledge gaps, 142  
     microscopic features, 140–141  
     prognosis and treatment, 142  
   progressive transformation of germinal centers (PTGCs), 67–68  
     clinical features, 68  
     immunophenotype, 68  
     pathologic features, 68  
     prognosis, 68  
 reactive eosinophilia, 62–63, 128  
   clinical features, 62  
   common causes, 65  
   differential diagnosis, 63, 128  
   pathogenesis, 62  
   pathological features, 62–63  
   prognosis and treatment, 63  
 reactive follicular hyperplasia (FH), 67, 296  
   differential diagnosis, 249  
   *see also* follicular hyperplasia (FH).  
 refractory anemia with excess blasts in transformation (RAEB-T), 151  
 refractory cytopenia of childhood (RCC), 148–150  
 retinoblastoma, 232  
 rhabdomyosarcoma (RMS), 229–231  
 rheumatoid arthritis, lymphoid hyperplasia and, 81  
 rickets, differential diagnosis, 142  
 Roberts syndrome, 36, 37, 39  
   differential diagnosis for TAR, 36  
 Rosai-Dorfman-Destombes disease (RDD), 339–341  
   cytogenetic and molecular genetic features, 341  
   differential diagnosis, 80, 341  
   immunophenotype, 341  
   morphology, 341  
   prognosis, 341  
 Rothmund-Thomson syndrome, 39  
 sarcoidosis, 76–77  
   clinical features, 76  
   differential diagnosis, 77  
   pathogenesis, 77  
   pathologic features, 77  
   prognosis and management, 77  
 scleroderma, lymphoid hyperplasia and, 81  
 Sebastian platelet syndrome, 55  
 Seckel syndrome, 39, 41  
 severe combined immunodeficiency (SCID), 296  
 severe congenital neutropenia (Kostmann syndrome), 175  
 severe congenital neutropenia (SCN), 28–32  
   ancillary diagnostic testing, 31  
   clinical features, 28  
   differential diagnosis, 31  
   genetics, 31  
   knowledge gaps, 32  
   microscopic features, 28  
   prognosis and management, 31

## Index

- Shwachman-Diamond syndrome (SDS), 42–43  
 ancillary diagnostic testing, 42  
 association with t-MNs, 175  
 clinical features, 42  
 diagnostic criteria, 43  
 differential diagnosis, 28, 39, 41, 43, 153  
 genetics, 42  
 knowledge gaps, 43  
 microscopic features, 42  
 prognosis and treatment, 43
- sickle cell anemia, 11–12  
 clinical features, 11  
 pathogenesis, 11  
 pathologic features, 11–12  
 prognosis, 12
- solid tumor  
 metastasis to BM, 227–233  
 risk of for DBA patients, 25  
*see also* metastatic tumor in the BM.
- spherocytosis, hereditary, *see* hereditary spherocytosis (HS).
- splenectomy  
 in management of HS, 15  
 as treatment for CDA, 14  
 as treatment for ITP, 59  
 as treatment for thalassemia patients, 11
- stem cell transplant  
 aplastic anemia, 46  
 BPDCN, 197  
 CAMT, 34  
 CNL, 143  
 DBA, 28  
 DKC, 41  
 FA, 39  
 JMML, 122  
 MDS, 148, 153  
 myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement, 128  
 osteopetrosis, 65  
 PMF, 142  
 SCN, 32  
 SDS, 43
- subcutaneous panniculitis-like T-cell lymphoma (SPTCL), 276–278  
 clinical features, 277  
 differential diagnosis, 272, 283  
 genetic features, 278  
 immunophenotype, 278  
 morphologic features, 277  
 prognosis, 278
- systemic EBV-positive T-cell lymphoma of childhood, 279–283  
 clinical features, 279–280  
 differential diagnosis, 281  
 epidemiology, 279  
 genetic features, 281  
 immunophenotype, 281  
 morphological features, 280  
 prognosis, 281
- systemic lupus erythematosus (SLE), 70–73  
 clinical features, 71  
 differential diagnosis, 73  
 immunophenotype, 72  
 KFD associated with, 70  
 lymphoid hyperplasia and, 81  
 pathologic features, 71  
 prognosis and treatment, 73
- systemic mastocytosis, differential diagnosis, 128, 142
- T-cell lymphomas, *see* hepatosplenic T-cell lymphoma (HSTCL); mature T-cell and NK-cell non-Hodgkin lymphomas; primary cutaneous T-cell lymphoma (CTCL); primary cutaneous CD30+ T-cell lymphoproliferative disorders (LPD).
- T-cell/histiocyte rich large B-cell lymphoma (THRLBCL), 246–248  
 clinical features, 247  
 differential diagnosis, 248, 249, 293  
 epidemiology, 246  
 genetic features, 248  
 immunophenotype, 248  
 morphologic features, 247  
 prognosis, 248
- T-cells, NK-cells and, 263
- telomere length, measuring, 40
- testing, *see* ancillary diagnostic testing; ancillary tests.
- thalassemias, 9–11  
 clinical features, 9, 10  
 pathogenesis, 9  
 pathologic features, 11  
 prognosis, 11
- therapy-related myeloid neoplasms (t-MNs), 175–177  
 clinical features, 175  
 differential diagnosis, 189  
 genetic disorders predisposing to, 175  
 genetic features, 176–177  
 immunophenotype, 176  
 pathogenesis, 175  
 pathological features, 175  
 prognosis, 177
- thrombocytopenia  
 causes of acquired thrombocytopenia in neonates and children, 35  
*see also* congenital amegakaryocytic thrombocytopenia (CAMT); thrombocytopenia-absent radii (TAR).
- thrombocytopenia-absent radii (TAR), 35–36  
 ancillary diagnostic testing, 35  
 clinical features, 35  
 differential diagnosis, 36  
 differential diagnosis for CAMT, 34  
 genetics, 36  
 knowledge gaps, 36  
 microscopic features, 35  
 prognosis, 36
- thymic hyperplasia, 81  
 clinical features, 81  
 differential diagnosis, 81, 224  
 pathological features, 81  
 prognosis and treatment, 81
- thymoma, differential diagnosis, 81, 224
- thyrotoxicosis, lymphoid hyperplasia and, 81
- T-lymphoblastic leukemia/lymphoma (T-ALL/LBL)  
 cytogenetic testing, 109  
 early T-cell precursor lymphoblastic leukemia (ETP-ALL), 224  
 not otherwise specified (T-ALL/LBL, NOS), 220–224  
 clinical features, 221  
 differential diagnosis, 224  
 genetic features, 223–224  
 immunophenotype, 222  
 morphologic features, 222  
 prognosis and treatment, 224
- T-lymphoblastic proliferations, indolent, 224
- toxoplasmosis lymphadenitis  
 clinical features, 94  
 differential diagnosis, 95, 123  
 pathogenesis, 94  
 pathologic features, 95  
 prognosis, 95
- transient abnormal myelopoiesis (TAM), 183–184  
 clinical features, 183  
 differential diagnosis, 184, 186, 189  
 genetic features, 184  
 immunophenotype, 184  
 pathologic features, 183  
 prognosis and management, 184
- tumor-associated macrophage accumulations, 317–319
- tyrosine kinase inhibitor therapy (TKI), 108, 133, 134, 215

Index

vitamin B12 and folate deficiency, 18–20	Warsaw breakage syndrome,	xanthogranulomatous inflammation,
clinical features, 19	37, 39	313–315
differential diagnosis, 20, 153	Wiskott-Aldrich syndrome	X-linked lymphoproliferative disease
pathogenesis, 19, 20	(WAS), 296	(XLP), 296
pathologic features, 19–20	differential diagnosis,	differential diagnosis, 80
prognosis and management, 20	34, 123	X-linked reticulate pigmentary disorder, 41